scholarly article | Q13442814 |
P8150 | COVIDWHO ID | covidwho-61388 |
P6179 | Dimensions Publication ID | 1126670293 |
P356 | DOI | 10.1159/000507582 |
P932 | PMC publication ID | 7179533 |
P698 | PubMed publication ID | 32289798 |
P2093 | author name string | David G Warnock | |
P2860 | cites work | Hydroxychloroquine: from malaria to autoimmunity | Q37827403 |
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? | Q90292620 | ||
Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade | Q90595084 | ||
P921 | main subject | pandemic | Q12184 |
COVID-19 pandemic | Q81068910 | ||
SARS-CoV-2 | Q82069695 | ||
COVID-19 | Q84263196 | ||
P304 | page(s) | 1-3 | |
P577 | publication date | 2020-04-14 | |
P1433 | published in | The Nephron Journals | Q15745443 |
P1476 | title | Clinical Trials during the SARS-CoV-2 Pandemic |
Q96768682 | A need for consensus on mortality reporting related to the COVID-19 pandemic in ongoing and future vascular registries and trials | cites work | P2860 |
Search more.